Business Context and Reporting Period
This Form 8-K is filed by Gemphire Therapeutics Inc. (not Metavia Inc.) on April 12, 2018. The report details a corporate governance action regarding an amendment to the company's equity incentive plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change to the company's Inducement Plan.
Material Changes
- Share Reserve Increase: On April 9, 2018, the Company amended its Inducement Plan to increase the aggregate number of shares of common stock available for issuance from 300,000 to 450,000 shares.
- Approval Process: The amendment was approved by the Compensation Committee of the Board of Directors without stockholder approval, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- Plan Terms: Other than the increase in the share reserve, the terms and conditions of the Inducement Plan remained unchanged.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the amendment to the equity plan.
Investor Verification Checklist
- Verify the exact terms of the Amendment attached as Exhibit 10.1.
- Confirm the remaining number of shares available under the plan post-amendment.
- Review the company's recent 10-K or 10-Q filings for actual financial performance data, as this 8-K does not contain financial statements.